title: Reduction in lung injury after combined surfactant and high-frequency ventilation.
abstract: Previous studies demonstrated that high-frequency oscillatory ventilation (HFOV) begun at birth limits the development of alveolar proteinaceous edema in premature monkeys at risk for hyaline membrane disease (HMD). We hypothesized that exogenous surfactant combined with HFOV would lead to even further reductions in edema. Twenty Macaca nemestrina monkeys were delivered at 134 d gestation (term = 168 d) and treated with either HFOV or conventional mechanical ventilation (CMV) from the first breath; modified bovine surfactant (Survanta [beractant]) was introduced into the trachea over the first few minutes of life. These animals were compared with 20 animals treated with either CMV or HFOV but without surfactant. At 6 h the lung was rapidly frozen in situ during inflation for determination of the volume fraction of alveolar edema. The combined use of surfactant and HFOV from the first breath reduced alveolar proteinaceous edema (3 +/- 1%; mean +/- SEM) from that seen with CMV alone (27 +/- 3%, p < 0.0001), CMV after surfactant (21 +/- 3%, p < 0.0001), and HFOV alone (13 +/- 3%, p < 0.015). We conclude that the use of surfactant with HFOV after premature birth is superior to either surfactant or HFOV alone in reducing lung injury during the first few hours of life. We speculate that this reduction in lung injury may reduce the incidence or severity of bronchopulmonary dysplasia.
authors.affiliation: Department of Pediatrics, Pathology, University of Washington, Seattle 98195.
authors.forename: J C
authors.initials: JC
authors.lastname: Jackson
authors.forename: W E
authors.initials: WE
authors.lastname: Truog
authors.forename: T A
authors.initials: TA
authors.lastname: Standaert
authors.forename: J H
authors.initials: JH
authors.lastname: Murphy
authors.forename: S E
authors.initials: SE
authors.lastname: Juul
authors.forename: E Y
authors.initials: EY
authors.lastname: Chi
authors.forename: J
authors.initials: J
authors.lastname: Hildebrandt
authors.forename: W A
authors.initials: WA
authors.lastname: Hodson
mesh_terms: D000818:Animals; D001688:Biological Products; D006612:High-Frequency Ventilation; D006801:Humans; D006819:Hyaline Membrane Disease / Q000473:pathology / Q000517:prevention & control*; D007231:Infant, Newborn; D008168:Lung / Q000473:pathology; D008254:Macaca nemestrina; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012121:Respiration, Artificial
chemical_list: D001688:Biological Products; D011663:Pulmonary Surfactants; C072197:beractant